| MACROGENICS INC. DL-,01 |
| USA |
| Gesundheit |
| US5560991094 / A1W6ND |
| M55 (Frankfurt) / MGNX (NASDAQ) |
| FRA:M55, ETR:M55, M55:GR, NASDAQ:MGNX |
| - |
| https://www.macrogenics.c.. |
|
MacroGenics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics primarily for cancer treatment. Its approved product, MARGENZA (margetuximab-cmkb), targets HER2-positive metastatic b..
>Volltext.. |
| 240.22 Mio. EUR |
| 197.7 Mio. EUR |
| 138.06 Mio. EUR |
| -49.72 Mio. EUR |
| -61.84 Mio. EUR |
| -0.98 EUR |
| 92.48 Mio. EUR |
| 58.46 Mio. EUR |
| -61.49 Mio. EUR |
| 1.61 |
| -4.52% |
| -18.04% |
| - |
| - |
| - |
| - |
| MACROGENICS |
| 24.07.26 |
|
||||
|
||||
|
||||
|